• 1
    Jenkin RDT, Boesel C, Ertel E, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. J Neurosurg. 1987; 66: 227233.
  • 2
    Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies in the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1992; 33: 10261030.
  • 3
    Packer RJ, Boyett JM, Zimmerman RA, et al. Brain stem gliomas of childhood: outcome after treatment with 7800 cGy of hyperfractionated radiotherapy, a Children's Cancer Group Phase I/II trial. Cancer. 1994; 74: 18271834.
  • 4
    Fu KK, Phillips TL. Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am. 1991; 5: 737749.
  • 5
    Friedman HS, Krischer PB, Oakes WG, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized Phase II study. J Clin Oncol. 1992; 10: 249256.
  • 6
    Allen J, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987; 5: 459463.
  • 7
    Schwachoffer JHM, Crookjmans RPM, Hoogenhout J, Kal HB, Theeuwes AGM. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys. 1991; 20: 12351241.
  • 8
    Schaake-Koning C, van cen Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992; 326: 524530.
  • 9
    Zinke H, Mockel B, Frey A, et al. Blood-brain barrier: a molecular approach to its structural and functional characterization. Progr Brain Res. 1992; 91: 103116.
  • 10
    Rapoport SI. Osmotic opening of the blood-brain barrier. Ann Neurol. 1988; 24: 677684.
  • 11
    Regoli D, Gobeil F, Nguyen QT, et al. Bradykinin receptor types and B2 subtypes. Life Sci. 1994; 55: 735749.
  • 12
    Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab. 1994; 14: 862870.
  • 13
    Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol. 1992; 20 (Suppl 9): S4S9.
  • 14
    Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog Cereport® increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther. 1994; 271: 229237.
  • 15
    Bartus RT, Elliott PJ, Hayward NJ, et al. Permeability of the blood brain barrier by the bradykinin agonist, Cereport®: evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology. 1996; 33: 270278.
  • 16
    Inamura T, Nomura T, Bartus RT, et al. Intracarotid infusion of Cereport®, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994; 81: 752758.
  • 17
    Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, Cereport®. Neurosurgery. 1996; 39: 125134.
  • 18
    Elliott PJ, Hayward NJ, Dean RL, et al. Intravenous Cereport® selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 1996; 56: 39984005.
  • 19
    Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood-brain barrier: a role for Cereport® in brain tumor therapy. Exp Neurol. 1996; 141: 214234.
  • 20
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
  • 21
    Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982; 38: 2941.
  • 22
    Warnke PC, Blasberg RG, Groothuis DR. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol. 1987; 22: 300305.
  • 23
    Hiesiger EM, Voorhies RM, Basler GA, et al. Opening the blood-brain and blood-tumors barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol. 1986; 19: 5059.
  • 24
    Elliott PJ, Hayward NJ, Dean RL, et al. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, Cereport®. Immunopharmacology. 1996; 33: 205208.
  • 25
    Black KL, Cloughesy T, Huang S-C, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg. 1997; 86: 603609.
  • 26
    Warren KE, Patel MC, Aikin AA, et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol. 2001; 48: 275282.
  • 27
    Gregor A, Lind M, Newman H, et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. J Neurooncol. 1999; 44: 137145.
  • 28
    Van Tassel P, Bruner JM, Maor MH, et al. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. Am J Neuroradiol. 1995; 16: 715726.
  • 29
    Allen J, Siffert J, DaRosso R, et al. Carboplatin as a radiopotentiating agent for newly diagnosed children with brainstem gliomas [abstract]. Ann Neurol. 1995; 38: 553.
  • 30
    Prados MD, Schold SC Jr., Fine HA, et al. A randomized, double-blind, placebo-controlled, Phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncology. 2003; 2: 96103.